Background
Phase III, open-label, randomized. First-line BRAF V600E-mutant metastatic colorectal cancer, ECOG 0-1. BRAF V600E occurs in 8-12% of mCRC and confers poor prognosis with standard chemotherapy. Tested addition of encorafenib + cetuximab to mFOLFOX6 chemotherapy backbone.
Interventions and follow up
Arm A (n=236): Encorafenib 300 mg daily + cetuximab + mFOLFOX6
Arm B (n=243): Standard chemotherapy (FOLFOX/CAPOX/FOLFOXIRI) ± bevacizumab
Primary endpoints: ORR by BICR and PFS
Median follow up: 16.8 months (experimental arm)
Arm B (n=243): Standard chemotherapy (FOLFOX/CAPOX/FOLFOXIRI) ± bevacizumab
Primary endpoints: ORR by BICR and PFS
Median follow up: 16.8 months (experimental arm)
Results
Progression-free survival: Median 12.8 vs 7.1 months, HR 0.53, 95% CI 0.41-0.68, P<.001
Overall survival: Median 30.3 vs 15.1 months, HR 0.49, 95% CI 0.38-0.63, P<.001
Objective response rate (BICR): Significantly higher with encorafenib + cetuximab + mFOLFOX6
Overall survival: Median 30.3 vs 15.1 months, HR 0.49, 95% CI 0.38-0.63, P<.001
Objective response rate (BICR): Significantly higher with encorafenib + cetuximab + mFOLFOX6
Adverse events
Overall: Grade ≥3 serious adverse events 46.1% (experimental) vs 38.9% (standard); permanent encorafenib discontinuation 14%
By system: Toxicities reflected expected agent profiles — neuropathy with the oxaliplatin backbone; gastrointestinal and dermatologic effects with cetuximab; safety profiles consistent with known agents and most events manageable
By system: Toxicities reflected expected agent profiles — neuropathy with the oxaliplatin backbone; gastrointestinal and dermatologic effects with cetuximab; safety profiles consistent with known agents and most events manageable
Conclusions
Encorafenib + cetuximab + mFOLFOX6 significantly prolonged both PFS and OS in first-line BRAF V600E-mutated mCRC versus standard chemotherapy ± bevacizumab, roughly doubling median OS and halving the risk of death.
Key Limitations
Open-label design; control arm allowed heterogeneous regimens; added toxicity of a three-drug targeted-plus-chemotherapy regimen requires careful patient selection; longer-term durability and quality-of-life data still maturing.
Clinical Context
BREAKWATER establishes encorafenib + cetuximab + mFOLFOX6 as a first-line standard for BRAF V600E-mutant mCRC, displacing chemotherapy ± bevacizumab and moving BRAF-targeted therapy into the frontline. The FDA granted full approval to the regimen in this setting in 2025; the regimen is incorporated into ESMO guidance.